Recent Advances in Ophthalmic Drug Delivery

Overview

Journal Ther Deliv

Date 2011 Mar 15

PMID 21399724

Citations 80

Authors

Uday B Kompella

Rajendra S Kadam

Vincent H L Lee

Affiliations

Soon will be listed here.

Abstract

Topical ocular drug bioavailability is notoriously poor, in the order of 5% or less. This is a consequence of effective multiple barriers to drug entry, comprising nasolacrimal drainage, epithelial drug transport barriers and clearance from the vasculature in the conjunctiva. While sustained drug delivery to the back of the eye is now feasible with intravitreal implants such as Vitrasert (-6 months), Retisert (-3 years) and Iluvien (-3 years), currently there are no marketed delivery systems for long-term drug delivery to the anterior segment of the eye. The purpose of this article is to summarize the resurgence in interest to prolong and improve drug entry from topical administration. These approaches include mucoadhesives, viscous polymer vehicles, transporter-targeted prodrug design, receptor-targeted functionalized nanoparticles, iontophoresis, punctal plug and contact lens delivery systems. A few of these delivery systems might be useful in treating diseases affecting the back of the eye. Their effectiveness will be compared against intravitreal implants (upper bound of effectiveness) and trans-scleral systems (lower bound of effectiveness). Refining the animal model by incorporating the latest advances in microdialysis and imaging technology is key to expanding the knowledge central to the design, testing and evaluation of the next generation of innovative ocular drug delivery systems.

Citing Articles

Therapeutic Assessment of Diverse Doxycycline-Based Formulations in Promoting Deep Corneal Wound Healing: Evidence from a Rat Model.

Chan S, Tseng C, Huang W, Lin C Vet Sci. 2025; 12(2).

PMID: 40005905 PMC: 11860526. DOI: 10.3390/vetsci12020143.

Drug Delivery Systems for Glaucoma: A Narrative Review.

Fea A, Vallino V, Cossu M, Marica V, Novarese C, Reibaldi M Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338326 PMC: 11435076. DOI: 10.3390/ph17091163.

Recent updates on ocular disease management with ophthalmic ointments.

Bisen A, Dubey A, Agrawal S, Biswas A, Rawat K, Srivastava S Ther Deliv. 2024; 15(6):463-480.

PMID: 38888757 PMC: 11285222. DOI: 10.1080/20415990.2024.2346047.

Advanced drug delivery and therapeutic strategies for tuberculosis treatment.

Nair A, Greeny A, Nandan A, Sah R, Jose A, Dyawanapelly S J Nanobiotechnology. 2023; 21(1):414.

PMID: 37946240 PMC: 10634178. DOI: 10.1186/s12951-023-02156-y.

Suprachoroidal Injection: A Novel Approach for Targeted Drug Delivery.

Wu K, Fujioka J, Gholamian T, Zaharia M, Tran S Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765048 PMC: 10535603. DOI: 10.3390/ph16091241.

References

Kompella U, Kim K, Lee V . Active chloride transport in the pigmented rabbit conjunctiva. Curr Eye Res. 1993; 12(12):1041-8. DOI: 10.3109/02713689309033501. View

Aukunuru J, Sunkara G, Ayalasomayajula S, Deruiter J, Clark R, Kompella U . A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm Res. 2002; 19(3):278-85. DOI: 10.1023/a:1014438800893. View

Del Amo E, Urtti A . Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today. 2008; 13(3-4):135-43. DOI: 10.1016/j.drudis.2007.11.002. View

Chiang C, TUNG S, Lu D, Yeh M . In vitro and in vivo evaluation of an ocular delivery system of 5-fluorouracil microspheres. J Ocul Pharmacol Ther. 2002; 17(6):545-53. DOI: 10.1089/10807680152729239. View

Hornof M, Bernkop-Schnurch A . In vitro evaluation of the permeation enhancing effect of polycarbophil-cysteine conjugates on the cornea of rabbits. J Pharm Sci. 2002; 91(12):2588-92. DOI: 10.1002/jps.10258. View

Wang W, Sasaki H, Chien D, Lee V . Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: a comparison with corneal penetration. Curr Eye Res. 1991; 10(6):571-9. DOI: 10.3109/02713689109001766. View

Akpek E, Vittitow J, Verhoeven R, Brubaker K, Amar T, Powell K . Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. J Ocul Pharmacol Ther. 2009; 25(5):433-9. DOI: 10.1089/jop.2009.0026. View

Loftsson T, Frithriksdottir H, Stefansson E, Thorisdottir S, Guthmundsson O, Sigthorsson T . Topically effective ocular hypotensive acetazolamide and ethoxyzolamide formulations in rabbits. J Pharm Pharmacol. 1994; 46(6):503-4. DOI: 10.1111/j.2042-7158.1994.tb03835.x. View

Kador P, Randazzo J, Babb T, Koushik K, Takamura Y, Zhu W . Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts. J Ocul Pharmacol Ther. 2007; 23(2):116-23. DOI: 10.1089/jop.2006.0112. View

10.

Nurieva S . [Effect on the eye vessels of vasodilator agents after their administration by different electrophoretic methods (clinical study)]. Vestn Oftalmol. 1978; (2):71-3. View

11.

Amrite A, Edelhauser H, Singh S, Kompella U . Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis. 2008; 14:150-60. PMC: 2254958. View

12.

Pearson P, Jaffe G, Martin D, Cordahi G, Grossniklaus H, Schmeisser E . Evaluation of a delivery system providing long-term release of cyclosporine. Arch Ophthalmol. 1996; 114(3):311-7. DOI: 10.1001/archopht.1996.01100130307014. View

13.

Kompella U, Bandi N, Ayalasomayajula S . Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003; 44(3):1192-201. DOI: 10.1167/iovs.02-0791. View

14.

Wei G, Xu H, Ding P, Li S, Zheng J . Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. J Control Release. 2002; 83(1):65-74. DOI: 10.1016/s0168-3659(02)00175-x. View

15.

Choonara Y, Pillay V, Danckwerts M, Carmichael T, du Toit L . A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases. J Pharm Sci. 2009; 99(5):2219-39. DOI: 10.1002/jps.21987. View

16.

Kapoor Y, Thomas J, Tan G, John V, Chauhan A . Surfactant-laden soft contact lenses for extended delivery of ophthalmic drugs. Biomaterials. 2008; 30(5):867-78. DOI: 10.1016/j.biomaterials.2008.10.032. View

17.

Sano K, Tokoro T, Imai Y . A new drug delivery system utilizing piggyback contact lenses. Acta Ophthalmol Scand. 1996; 74(3):243-8. DOI: 10.1111/j.1600-0420.1996.tb00085.x. View

18.

Gehlbach P, Demetriades A, Yamamoto S, Deering T, Duh E, Yang H . Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization. Gene Ther. 2003; 10(8):637-46. DOI: 10.1038/sj.gt.3301931. View

19.

MAURICE D . Iontophoresis of fluorescein into the posterior segment of the rabbit eye. Ophthalmology. 1986; 93(1):128-32. DOI: 10.1016/s0161-6420(86)33781-3. View

20.

Lee Y, Lee V . Formulation influence on ocular and systemic absorption of topically applied atenolol in the pigmented rabbit. J Ocul Pharmacol. 1993; 9(1):47-58. DOI: 10.1089/jop.1993.9.47. View